In the present study, we investigated the signaling pathway involved in luteinizing hormone (LH)-mediated regulation of testicular CYP1B1 in mouse MA-10 and rat R2C Leydig cells. CYP1B1 mRNA and protein levels were measured in MA-10 and R2C cells treated with LH and protein kinase activators or inhibitors. Treatment with LH or 8-bromo-cAMP, a protein kinase A (PRKA) activator, increased CYP1B1 expression and PRKA activity in a concentration-dependent manner in both cell lines, albeit to different extents. Treatment with 8-(4-chlorophenylthio)adenosine-3 0 ,5 0 -cyclic monophosphorothioate, Rpisomer, a PRKA inhibitor, decreased basal CYP1B1 expression and attenuated LH-elicited increases in CYP1B1 mRNA and protein levels and PRKA activity. In contrast, treatment with a protein kinase G activator or an inhibitor of protein kinase C had no effect on basal or LH-induced CYP1B1 expression in MA-10 or R2C cells. Collectively, the results identify PRKA as the major signaling pathway involved in the LH-mediated regulation of testicular CYP1B1 expression in Leydig tumor cells.
INTRODUCTION
Mammalian testis contains steroidogenic cytochrome P450 (CYP) enzymes such as CYP11A1 and CYP17A1 that catalyze key steps in androgen biosynthesis [1] and a second group of CYP enzymes that function in the conversion of lipophilic endogenous and xenobiotic compounds to more water-soluble metabolites [2] . CYP1B1, which belongs to the latter group, may be the most abundantly expressed CYP enzyme in the testis of adult male rats [3] . The physiological function of CYP1B1 remains a puzzle. CYP1B1 catalyzes the hydroxylation of 17b-estradiol to 4-hydroxyestradiol, a carcinogenic metabolite in animal models [4] , and can oxidize catechol estrogens to reactive semiquinone and quinone intermediates [5] . In addition, CYP1B1 catalyzes the metabolic activation of polycyclic aromatic hydrocarbons such as benzo[a]pyrene and 7,12-dimethylbenz [a] anthracene to genotoxic metabolites and may be involved in mediating xenobiotic-elicited testicular toxicity [6, 7] .
CYP1B1 expression is subject to developmental and hormonal regulation in the rat testis [3, 8] . Recent work from our laboratory showed that testicular CYP1B1 protein expression increases during puberty and is down-regulated by hypophysectomy [3] . CYP1B1 protein levels can be partially restored in hypophysectomized rats by treatment with luteinizing hormone (LH) or follicle-stimulating hormone (FSH), alone or in combination with prolactin [3] . The molecular basis by which LH and FSH increased CYP1B1 protein levels in vivo is not known but may be similar to the mechanisms involved in regulating testicular steroidogenesis. LH is the principal regulator of steroidogenic function in Leydig cells [9] . LH receptor (Lhcgr) activation and increased intracellular levels of 3 0 ,5 0 -cyclic adenosine monophosphate (cAMP) with subsequent stimulation of protein kinase A (PRKA) activity is the major signaling pathway by which LH increases expression of genes encoding steroidogenic enzymes in testes [10] . However, other signal transduction pathways involving phospholipase C, protein kinase C (PRKC), and mitogen-activated protein kinase can also modulate Leydig cell function [11] [12] [13] . The regulation of CYP1B1 may have pathological implications because increased expression of CYP1B1 has been reported for several types of human cancers, including breast, endometrial, prostate, and testicular tumors, relative to normal tissues [14, 15] .
Leydig tumor cell lines are useful ex vivo models for assessing hormonal effects and the involvement of signaling pathways in the regulation of testicular CYP enzymes. The MA-10 cell line is an immortalized clonal cell line derived from a transplantable Leydig cell tumor that originated spontaneously in C57BL/6 mice [16] . MA-10 cells retain many of the characteristics of normal Leydig cells, including low levels of functional Lhcgr [17] . However, MA-10 cells do not have measurable steroid 17a-hydroxylase (CYP17A1) activity and do not produce testosterone constitutively [18] . Treatment of MA-10 cells with LH, human chorionic gonadotropin, or cAMP analogs leads to increased CYP17A1 expression and stimulation of steroidogenesis by .500-fold [16, [19] [20] [21] [22] . In contrast, R2C cells were derived from a Leydig cell tumor in the testis of a 2-mo-old rat (WFu strain) [23] . R2C cells exhibit high basal steroidogenic and PRKA activities relative to MA-10 cells and constitutively synthesize testosterone and progesterone, but are less responsive to treatment with cAMP analogues and hormones than MA-10 cells [22, 24, 25] . We recently demonstrated that CYP1B1 protein is highly expressed in R2C cells and that CYP1B1 regulation in R2C and MA-10 cells is similar to that found in vivo insofar as CYP1B1 was not inducible in rat testis, R2C cells, or MA-10 cells by treatment with aryl hydrocarbon receptor agonists such as 2,3,7,8-tetrachlorodibenzo-p-dioxin [26] .
The purpose of the present study was to investigate the signal transduction pathway involved in LH-mediated regulation of testicular CYP1B1 expression in mouse and rat Leydig cells. The effects of treatment with exogenous LH and with protein kinase activators or inhibitors on CYP1B1 protein and mRNA levels, Lhcgr mRNA expression, and PRKA activity were determined and compared in MA-10 mouse and R2C rat Leydig tumor cells.
MATERIALS AND METHODS

Chemicals
Agarose, TRIzol, SuperScript II reverse transcriptase, deoxyribonuclease I, oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer, dithiothreitol, platinum Taq DNA polymerase, and 2 0 -deoxynucleoside-5 0 -triphosphate (dNTP) mix were purchased from Invitrogen Canada (Burlington, ON). Forward and reverse primers for mouse Cyp1b1, bactin (Actb), and Lhcgr were synthesized at the Nucleic Acid and Protein Service Unit, The University of British Columbia (Vancouver, BC). LH (from sheep pituitary), FSH (from porcine pituitary), prolactin (from sheep pituitary),
0 ,5 0 -cyclic monophosphorothioate, Rp-isomer (Rp-CPT-cAMP), dextran, Triton-X 100, benzamidine, b-glycerolphosphate, ethylene glycol bis-(2-aminoethyl ether) tetraacetic acid (EGTA), 4-morpholinepropanesulfonic acid (MOPS), leupeptin, aprotinin, ethylenediaminetetraacetic acid (EDTA), phenylmethanesulfonyl fluoride (PMSF), and sodium vanadate were purchased from Sigma-Aldrich (St. Louis, MO).
-dione (Go 6983) was purchased from Calbiochem (San Diego, CA). Rat CYP1B1-selective (anti-peptide) antiserum (catalog no. 458511) and cDNA-expressed rat CYP1B1 proteins were purchased from BD-Gentest (Woburn, MA). Rat CYP1B1 protein exhibits 94% amino acid sequence identity with mouse CYP1B1. Goat polyclonal antihexose-6-phosphate dehydrogenase (H6PD) immunoglobulin G (IgG) and alkaline phosphatase-conjugated swine anti-goat IgG (H plus L chains) were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA) and Cedarlane Labs (Burlington, ON), respectively. All the other chemicals were obtained as indicated previously [3, 27] .
Cell Culture and Treatments
The MA-10 tumor cells were a generous gift from Dr. Mario Ascoli (University of Iowa, IA). The R2C tumor cells were obtained from the American Type Culture Collection (Manassas, VA). MA-10 cells were cultured in RPMI 1640 growth medium supplemented with 15% heat-inactivated horse serum, 20 mM Hepes, 50 lg/ml gentamycin, and 2 mM glutamine (Invitrogen Life Technologies, Burlington, ON). R2C cells were grown in Ham's F-10 nutrient medium supplemented with 15% horse serum and 2.5% (vol/vol) fetal bovine serum, 50 units/ml penicillin, and 50 lg/ml streptomycin (Invitrogen Life Technologies). Both cell lines were maintained in a humidified atmosphere of 5% CO 2 /95% air at 378C. MA-10 cells were grown in T25 flasks by plating approximately 10 6 cells/flask and R2C cells were grown in T75 flasks by plating approximately 2 3 10 6 cells/flask for 6 days in a humidified atmosphere of 5% CO 2 and 95% air at 378C. When the cells reached 75%-80% confluence (typically 1 wk after the cells were started in the growth medium), the growth medium was replaced by serum-free medium and the cells were exposed to various concentrations of the following hormones, test compounds, or the respective vehicle-water or dimethyl sulfoxide (DMSO) at 0.1% (v/v)-for varying periods: LH, FSH, or prolactin dissolved in water, either alone or in combination; 8-Br-cAMP dissolved in water or DMSO; H89 or Go 6983 dissolved in DMSO; or Rp-CPT-cAMP or 8-Br-cGMP dissolved in water. Concentration-response and time-course studies were carried out for each treatment, and each treatment was repeated three to five times on different days. Cyp1b1 and Lhcgr mRNA levels, PRKA activity, and cell cytotoxicity were determined using MA-10 cells. CYP1B1 protein levels, PRKA activity, and cell viability were determined using R2C cells.
Preparation of R2C Cell Microsomes
Microsomal fractions were prepared from R2C rat Leydig cells as follows: Culture medium was removed from the flasks at the end of the treatment period, and R2C cells were washed by incubating the cells on ice for 20 min with 5 ml of ice-cold 0.5 M Tris buffer (pH 7.4) containing 1.15% KCl. Cells were scraped into prechilled microcentrifuge tubes, and the microsomes were prepared from cell homogenates by differential ultracentrifugation as described previously [27] . Total protein concentration in each microsomal sample was determined by the method of Lowry et al. [28] using bovine serum albumin as the protein standard.
Immunoblot Analysis
CYP1B1 protein levels were measured in R2C cell microsomal samples by immunoblot analysis. H6PD protein levels were measured in the same samples as a loading control. Microsomal proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrophoretically transferred onto nitrocellulose membranes as described previously [27] . Membranes were incubated with rabbit anti-rat CYP1B1 serum (1:500 dilution; BD-Gentest) at 378C for 2 h, followed by a 2 h incubation with alkaline phosphataseconjugated goat [Fab 0 ] 2 anti-rabbit IgG (diluted 1:3000; Biosource, Camarillo, CA). After detection of CYP1B1, the same membranes were washed, without stripping, and incubated with goat anti-H6PD IgG (1:100 dilution) overnight at 58C, followed by a 2 h incubation with alkaline phosphatase-conjugated swine anti-goat IgG (dilution of 1:2000) . Immunoreactive CYP1B1 and H6PD protein bands were visualized by alkaline phosphatase-based colorimetric detection and quantified with a pdi 420oe scanning densitometer using Quantity One Version 3.0 software (pdi Inc., Huntington Station, NY) as described previously [3, 28] . Rat recombinant CYP1B1 was loaded on gels at a range of concentrations (0.05-1 pmol/lane) as a calibration standard for quantification of CYP1B1 protein levels in microsomal samples [3, 29] .
Isolation of Total RNA and Multiplex Reverse Transcription (RT)-PCR
At the end of the treatment period, the culture medium was removed from the flasks, and MA-10 cells were washed with ice-cold PBS containing 137 mM sodium chloride, 2.6 mM potassium chloride, 8.1 mM sodium phosphate, 1.5 mM potassium dihydrogen phosphate, 0.2 mM EDTA, pH 7.4. MA-10 cells were then treated with TRIzol reagent following the manufacturer's instructions for preparation of total RNA. The purity and concentration of each RNA preparation were determined (using Genespec software; MiraiBio Group, South San Francisco, CA) by the absorbance ratio at 260 and 280 nm. RNA preparations with a ratio ! 1.9 were used for subsequent experiments. The integrity of the RNA preparations was evaluated by electrophoresis on a 1.7% agarose gel containing 0.66 M formaldehyde.
Complementary DNA was prepared from total RNA using SuperScript II reverse transcriptase as described previously [3, 30] and was stored at À208C for subsequent use in PCR. For PCR analysis, the oligonucleotide sequences (5 0 -GGCGTTCGGTCACTACTCTG-3 0 , forward, and 5 0 -AGGTTGGGCTGGT CACTCAT-3 0 , reverse) were used to amplify a 737-bp region of mouse Cyp1b1 gene [31] ; (5 0 -GTGGGCCGCTCTAGGCACCAA-3 0 , forward, and 5 0 -CTCTTTGATGTCACGCACGATTTC-3 0 , reverse) were used to amplify a 525-bp region of mouse Actb gene [32] ; and (5 0 -CTCACCTATCTCCCTGT CAAAGT-3 0 , forward, and 5 0 -ATGGACTCATTATTCATCCCTTG-3 0 , reverse) were used to amplify a 365-bp region of mouse Lhcgr gene [33] . Each 25-ll aliquot of PCR reaction mixture contained PCR reaction buffer, 5 ll of cDNA, 2 mM magnesium chloride, 400 lM dNTP, 0.2 lM each of the forward and reverse primers, and 2 units of platinum Taq polymerase enzyme. The amplification reaction was initiated by heating at 948C for 2 min. This was followed by 25 cycles (for Actb), 38 cycles (for Lhcgr), or 42 cycles (for Cyp1b1) using the following thermocycling conditions: 60 sec of denaturation at 948C, 30 sec of annealing at 608C, and 1 min (for Lhcgr) or 2 min (for Cyp1b1) of extension at 728C. A final incubation was carried out for 10 min at 728C. After thermocycling, final PCR products were subjected to electrophoresis using 1.7% agarose gels, and ethidium bromide-stained band intensities were quantified using the LabWork software program (UVP Inc., Cambridge, U.K.).
PRKA Activity Assay
PRKA activity was measured in cytosolic fractions of MA-10 cells and R2C cells. Culture medium was removed from the flasks at the end of the treatment period and cells were washed with 5 ml of ice-cold PBS per flask. Cells were incubated for 10 min with lysis buffer (1 ml/flask) containing 20 mM MOPS, 50 mM b-glycerolphosphate, 50 mM sodium fluoride, 1 mM sodium vanadate, 5 mM EGTA, 2 mM EDTA, 1% Nonidet P-40, 1 mM dithiothreitol, 1 mM benzamidine, 1 mM PMSF, 10 lg/mL leupeptin, and 10 lg/mL aprotinin. After the incubation period, the cells were scraped off and transferred into prechilled microcentrifuge tubes and sonicated briefly to lyse the cells. Cell lysates were spun in a tabletop centrifuge for 15 min at 13 000 rpm, and the resulting supernatant containing the cytosolic fraction was collected. Protein concentration was determined using the Lowry protein assay [28] . PRKA activity was measured using a sensitive nonradioactive commercial assay kit (Stressgen Biotechnologies, San Diego, CA) following the manufacturer's instructions. The solid-phase ELISA used a specific synthetic peptide as a substrate for PRKA and a polyclonal antibody that recognized the phosphorylated form of the substrate. A peroxidase-conjugated secondary 90 DEB AND BANDIERA antibody was subsequently added to each well, followed by the 3,3 0 ,5,5 0 -tetramethylbenzidine substrate solution supplied as a kit (Stressgen Biotechnologies, San Diego, CA). Absorbance was measured at 450 nm using a microplate reader (model EL309; Bio-Tek Instruments, Inc., Winooski, VT). Relative PRKA activity was calculated as the difference between the PRKA activity of cell lysates and the blank, which contained all the components of the assay except for the cell lysate, divided by the amount of protein (in lg).
Cytotoxicity Assay
The cytotoxic effect of treatment on MA-10 and R2C cells was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)-based commercial assay kit (Sigma-Aldrich) following the manufacturer's instructions. Briefly, cells were grown in 96-well plates and were treated with hormones and test compounds as described above. Triton X-100 (1%) and dextran (5%) were used as positive and negative controls, respectively. At the end of the treatment period, 20 ll of MTT solution was added to each well and incubated for 4 h. Absorbance, which served as an estimation of the intact functional mitochondria and is an indicator of cell viability in the wells, was measured spectrophotometrically at 540 nm using a microplate reader.
Statistical Analysis
Parametric tests were used when the data passed the normality and equal variance test. Nonparametric tests were used when the data failed to pass the normality test and equal variance test (SigmaStat Statistical Software, Version 3.1; SPSS Inc., Chicago, IL). Differences between the mean values of two treatment groups were assessed by the Student t-test (parametric) or the MannWhitney test (nonparametric unpaired t-test). When there were more than two groups, data were analyzed by one-way ANOVA (parametric) or KruskalWallis one-way ANOVA test (nonparametric), followed by the Student Newman-Keuls multiple comparison test. Different treatment groups were compared with the control and with each other. All the statistical analyses were performed using the SigmaStat software program Version 3.1. The level of significance was set a priori at P , 0.05.
RESULTS
Luteinizing Hormone Up-Regulates Cyp1b1 Expression in MA-10 Cells in a Concentration-Dependent Manner
We previously showed that treatment with LH, alone or in combination with FSH and prolactin, partially restored testicular CYP1B1 expression in hypophysectomized adult rats [3] . To determine if Cyp1b1 expression in Leydig tumor cells in culture was similarly responsive to gonadotropins and prolactin, MA-10 mouse Leydig cells were treated for 12 h with LH, FSH, or prolactin, either individually-each at a concentration of 0.05 international units (IU)/ml of culture medium-or in combination. As shown in Figure 1A , treatment with LH increased Cyp1b1 mRNA expression compared to control (vehicle-treated) cells. Relative Cyp1b1 mRNA levels were increased to a lesser extent after treatment with FSH or prolactin. Cotreatment with LH and FSH, with LH and prolactin, or with LH, FSH, and prolactin was not more effective than LH treatment alone. CYP1B1 protein was not detected in MA-10 cells despite our efforts using several commercial sources of antibody to mouse CYP1B1.
The responsiveness of MA-10 cells to LH was further assessed by treating cells with varying LH concentrations (0.01-0.2 IU/ml) for 12 h. Concentration-dependent increases in relative Cyp1b1 mRNA levels in MA-10 cells were observed Cyp1b1 mRNA levels were determined by RT-PCR followed by densitometric analysis of ethidium bromide-stained agarose gels and are expressed relative to the intensity of the corresponding Actb mRNA band. Mean 6 SD values from three to five separate experiments performed on different days are shown. Data were analyzed using one-way ANOVA (parametric), followed by the Student Newman-Keuls multiple comparison test. Letters a-d indicate that Cyp1b1 mRNA levels of the labeled treatment groups are significantly different (P , 0.05) from that of the control (vehicle-treated) group. Treatment groups labeled with different letters are significantly different (P , 0.05) from each other, whereas groups labeled with the same letter are not statistically different from one another with respect to Cyp1b1 mRNA levels. LH-MEDIATED REGULATION OF TESTICULAR CYP1B1 BY PRKA (Fig. 1B) . Increased Cyp1b1 mRNA levels in MA-10 cells were observed as early as 3 h after treatment with LH at a concentration of 0.05 IU/ml and were greater after 12 h than 24 h of treatment (Supplemental Fig. S1 , all the supplemental data are available online at www.biolreprod.org). LH treatment also elicited a concentration-dependent increase in PRKA activity and a concentration-dependent decrease in relative Lhcgr mRNA levels in MA-10 cells (Supplemental Fig. S2 ) as expected [11, [34] [35] [36] . There was no evidence of cytotoxicity following treatment with LH or other hormones at the concentrations used in the study (data not shown). . Cyp1b1 mRNA levels were determined by RT-PCR followed by densitometric analysis of ethidium bromide-stained agarose gels and are expressed relative to the intensity of the corresponding Actb mRNA band. Relative PRKA activity was determined in the cytosolic fraction of cell lysates using a nonradiometric ELISA assay. Mean 6 SD values from three to five separate experiments performed on different days are shown. Data in panel A and Cyp1b1 mRNA data in panel B were analyzed using oneway ANOVA (parametric), and PRKA activity data in panel B were analyzed using Kruskal-Wallis one-way ANOVA test 
FIG. 4. Effect of cotreatment with Rp-CPT-cAMP or Go 6983 and LH on
Cyp1b1 mRNA expression and PRKA activity in MA-10 mouse Leydig tumor cells. MA-10 cells were preincubated with Rp-CPT-cAMP (25 lM) for 1 h followed by treatment with LH (0.01-0.2 IU/ml) for 12 h (panel A) or were preincubated with Go 6983 (100 lM) for 1 h followed by treatment with LH (0.01-0.2 IU/ml) for 12 h (panel B). As a positive control, MA-10 cells were treated with LH (0.05 IU/ml) without preincubation with inhibitors. Cyp1b1 mRNA levels were determined by RT-PCR followed by densitometric analysis of ethidium bromidestained agarose gels and are expressed relative to the intensity of the corresponding Actb mRNA band. Relative PRKA activity was determined using a nonradiometric ELISA assay. Mean 6 SD values from three to five separate experiments performed on different days are shown. Differences in Cyp1b1 mRNA levels between each treatment group and the control group were assessed by the Student t-test (parametric), and differences in PRKA activity between each treatment group and the control group were assessed by the Mann-Whitney test (nonparametric unpaired t-test). When more than two groups were compared, Cyp1b1 mRNA data were analyzed by one-way ANOVA (parametric), and PRKA activity data were analyzed by the Kruskal-Wallis one-way ANOVA test (nonparametric) followed by the Student Newman-Keuls multiple comparison test. Letter a indicates significant difference (P , 0.05) from the corresponding values of the control (vehicle-treated) group; b, significantly different (P , 0.05) from the corresponding values of the group treated with a kinase inhibitor (Rp-CPT-cAMP or Go 6983) alone (second group from the left in panels A and B); and c, the Cyp1b1 mRNA and PRKA activity values of the group treated with LH (0.05 IU/ml) alone (right-hand group in panel A) are significantly different (P , 0.05) from the corresponding values of the group treated with Rp-CPT-cAMP plus LH (0.05 IU/ml) (fourth group from the right in panel A). Treatment with Rp-CPT-cAMP (25 lM) alone significantly decreased (P , 0.05) the Cyp1b1 mRNA level and PRKA activity by 62% and 64%, respectively, compared to the control group. Treatment with Rp-CPT-cAMP (25 lM) plus LH (0.05 IU/ml) increased the Cyp1b1 mRNA level and PRKA activity by approximately 2-fold compared to the group treated with Rp-CPT-cAMP alone. However, the Cyp1b1 mRNA level and PRKA activity remained significantly below (P , 0.05) those of the control group. Treatment with LH (0.05 IU/ml) alone increased the Cyp1b1 mRNA level and PRKA activity by 3.3-and 2-fold, respectively, compared to the control group, and by 4.4-and 3-fold, respectively, compared to the group treated with Rp-CPT-cAMP (25 lM) plus LH (0.05 IU/ml).
DEB AND BANDIERA
Effect of PRKA Activators and Inhibitors on Cyp1b1 Expression in MA-10 Cells
The role of the PRKA-signaling pathway in the regulation of basal Cyp1b1expression was investigated by treating MA-10 cells with PRKA activators and inhibitors in the absence of LH stimulation. Treatment of MA-10 cells with varying concentrations (0.25-2 mM) of 8-Br-cAMP, a synthetic nonhydrolyzable cAMP analog, for 6 h resulted in concentration-dependent increases in relative Cyp1b1 mRNA levels and relative PRKA activity (Fig. 2) and concentration-dependent decreases in Lhcgr mRNA levels (Supplemental Fig. S3 ). Elevated Cyp1b1 mRNA levels were observed as early as 3 h after treatment, and the largest increase was observed after 6 and 12 h of treatment with 8-Br-cAMP at a concentration of 1 mM (Supplemental Fig. S4 ). Treatment of MA-10 Leydig tumor cells with varying concentrations of either H89 (1-100 lM) , an inhibitor of PRKA and other kinases, or Rp-CPT-cAMP (1-150 lM) , an inhibitor of PRKA type I and II, for 1 h resulted in concentrationdependent decreases in Cyp1b1 mRNA expression (Fig. 3) . In MA-10 cells, Cyp1b1 mRNA levels were reduced by approximately two-thirds compared to vehicle-treated cells after treatment with H89 at a concentration of 100 lM for 1 h (Fig.  3A) and by a similar extent after treatment with Rp-CPT-cAMP at a concentration of 150 lM for 1 h (Fig. 3B) . The suppressive effects of H89 and Rp-CPT-cAMP (25 lM) on Cyp1b1 mRNA expression in MA-10 cells were time-dependent and were observed as early as 30 min after treatment (Supplemental Fig.  S5 ). There was no evidence of cytotoxicity following treatment of MA-10 cells with 8-Br-cAMP, H89, or Rp-CPT-cAMP at the concentrations used in the study (data not shown). 150 lM) or with water for 6 h (panel B), or preincubated with Rp-CPT-cAMP (25 lM) for 1 h followed by treatment with LH (0.2 IU/ ml) or 8-Br-cAMP (2 mM) for 12 h (panel C); CYP1B1 protein levels and relative PRKA activities were measured. For panels A, B, and C, the insets show representative immunoblots of CYP1B1 protein in microsomes prepared from R2C cells. Lanes 1-4 and 1-6 correspond to the same treatments (left to right) as on the corresponding histogram. Equal amounts of microsomal protein (20 lg) were loaded in each lane, and blots were probed with rabbit anti-rat CYP1B1 serum or with goat anti-H6PD IgG. CYP1B1 protein levels were measured by densitometric analysis as described in the Materials and Methods section. Relative PRKA activity was determined in the cytosolic fraction of cell lysates using a nonradiometric ELISA assay. Mean 6 SD values from four separate experiments performed on different days are shown. Differences between each treatment group and the control group were assessed by the Student t-test (parametric). When more than two groups were compared, data were analyzed using one-way ANOVA (parametric) followed by the Student Newman-Keuls multiple comparison test. Letters a-c indicate that the CYP1B1 protein or PRKA activity values of the labeled treatment groups are significantly different (P , 0.05) from the corresponding values of the control (vehicle-treated) group. Treatment groups labeled with different letters are significantly different (P , 0.05) from each other with respect to CYP1B1 protein or PRKA activity values. Groups labeled with the same letter are not statistically different from one another with respect to CYP1B1 protein or PRKA activity values. (3-24 h ) (data not shown). Treatment of MA-10 cells with 8-Br-cGMP or Go 6983 at the concentrations used in this study had no effect on Cyp1b1 mRNA levels (data not shown), suggesting that the PRKG and PRKC pathways do not play a role in basal Cyp1b1 expression in MA-10 mouse Leydig cells.
LH-MEDIATED REGULATION OF TESTICULAR CYP1B1 BY
PRKA GMP analog and PRKG activator, or with varying concentrations (1-200 lM) of Go 6983, an inhibitor of PRKC, for varying periods
Effect of Cotreatment of MA-10 Cells with LH and PRK Inhibitors
The dependence of Cyp1b1 induction by LH on PRKA activation was investigated by cotreating MA-10 cells with Rp-CPT-cAMP and LH. MA-10 cells were first incubated with Rp-CPT-cAMP (25 lM) for 1 h followed by treatment with increasing concentrations (0.01-0.2 IU/ml) of LH for 12 h. As a positive control, cells were treated with LH alone at a concentration of 0.05 IU/ml. As shown in Figure 4A , the suppressive effect of Rp-CPT-cAMP on Cyp1b1 mRNA expression and PRKA activity was reversed by cotreatment with LH in a concentration-dependent manner. Cyp1b1 mRNA expression and PRKA activity remained significantly different from those of the control (vehicle-treated) group following cotreatment with LH at concentrations of 0.01, 0.02, or 0.05 IU/ml. Cyp1b1 mRNA expression was restored to basal levels at higher concentrations of LH but was not induced above basal levels (Fig. 4A) . Comparable results were obtained after cotreatment with H89 (25 lM) and LH (0.01-0.2 IU/ml) (Supplemental Fig. S6) .
Similar experiments were performed in MA-10 cells using cotreatment with H89 (25 lM) and 8-Br-cAMP (0.25-1 mM), a PRKA activator, in place of LH. As was observed with LH cotreatment, the suppressive effect of H89 on Cyp1b1 mRNA levels and PRKA activity was reversed by cotreatment with 8-Br-cAMP in a concentration-dependent manner. Cyp1b1 mRNA levels and PRKA activity were restored to levels similar to those of the control group following cotreatment with 8-Br-cAMP at concentrations of 1 or 2 mM (Supplemental Fig.  S7 ). In the next experiment, MA-10 cells were treated with Go 6983 (100 lM) for 1 h followed by treatment with LH at various concentrations (0.01-0.2 IU/ml) for 12 h to determine if the PRKC pathway was involved in mediating Cyp1b1 induction by LH. Treatment with Go 6983 did not suppress basal Cyp1b1 mRNA levels and did not attenuate induction of Cyp1b1 mRNA expression by LH (Fig. 4B) . In fact, Cyp1b1 mRNA levels were induced above basal levels following cotreatment with Go 6983 and LH at concentrations of 0.02 IU/ ml and higher. Taken together, the findings of the cotreatment experiments strongly suggest that up-regulation of Cyp1b1 expression by LH was mediated by activation of the PRKAsignaling pathway and that the PRKC pathway plays little or no role in MA-10 mouse Leydig cells.
LH-Mediated Regulation of CYP1B1 Protein Expression in Rat R2C Leydig Cells
LH-mediated regulation of CYP1B1 was investigated in rat R2C Leydig cells, which maintain high levels of basal steroidogenic activity. In contrast to MA-10 cells, CYP1B1 protein was readily visualized and quantified by immunoblot analysis using a commercially available antibody. CYP1B1 protein levels were increased by approximately 30% in R2C cells treated with LH at concentrations of 0.2 IU/ml for 12 h, relative to vehicle-treated cells (Fig. 5A) . A similar increase in CYP1B1 protein levels was observed after treatment with 8-BrcAMP at a concentration of 2 mM for 12 h (Fig. 5C) . PRKA activity was also increased in R2C cells following treatment with LH (0.2 IU/ml) or 8-Br-cAMP (2 mM) (Fig. 5C ). Basal PRKA activity in R2C cells was approximately 2-fold higher than in MA-10 cells.
Treatment of R2C cells with Rp-CPT-cAMP (1-150 lM) for 6 h decreased CYP1B1 protein levels and PRKA activity, compared to the vehicle-treated group (Fig. 5B) . In contrast, treatment of R2C cells with Go 6983 (1-200 lM) had no effect on basal CYP1B1 protein levels (data not shown). Following cotreatment of R2C cells with Rp-CPT-cAMP (25 lM) and either LH (0.2 IU/ml) or 8-Br-cAMP (2 mM) for 12 h, CYP1B1 protein expression and PRKA activity were similar to those of the control group but less than the levels obtained in the absence of Rp-CPT-cAMP (Fig. 5C ). There was no evidence of cytotoxicity in R2C cells following treatment with LH or other chemicals at the concentrations used in the study (data not shown). Collectively, the findings demonstrate that basal CYP1B1 expression and CYP1B1 induction in rat Leydig cells are linked to cellular PRKA activity.
DISCUSSION
Mouse Leydig tumor cells (MA-10) and rat Leydig tumor cells (R2C) were used to elucidate the mechanism for the LHmediated regulation of CYP1B1 in Leydig cells. The major findings of our study are that LH is a major regulator of CYP1B1 expression in mouse and rat Leydig tumor cells and that basal expression and LH-elicited induction of CYP1B1 in Leydig cells are coupled to the cAMP-activated PRKA pathway.
CYP1B1 is predominantly an extrahepatic CYP enzyme that is up-regulated in human tumors [14] and is highly expressed in human and rodent steroidogenic tissues such as the adrenal gland, ovary, and testis [8, 15] . Results from our current study indicate that the regulation of CYP1B1 in testis differs from that in other steroidogenic and nonsteroidogenic tissues. For example, our results demonstrate that testicular CYP1B1 is regulated primarily by LH. In contrast, LH had no effect on CYP1B1 expression in rat ovarian granulosa cells [37] and adrenocorticotropic hormone-regulated CYP1B1 expression in rat adrenal cortex and cultured adrenocortical cells [38, 39] . Moreover, CYP1B1 expression in testis differs from liver, lung, and other tissues including breast epithelial cells and rat adrenocortical cells [2, 8, 31, 39, 40] because it is not responsive to aryl hydrocarbon receptor-mediated induction [26] .
Induction of CYP1B1 by LH and cAMP analogs was not attributable to increased Lhcgr expression because treatment with LH and 8-Br-cAMP down-regulated Lhcgr expression in a concentration-and time-dependent fashion. Nelson and Ascoli [35] and Tsuchiya et al. [36] previously reported decreased Lhcgr expression in MA-10 cells after treatment with LH and 8-Br-cAMP, possibly due to overproduction of steroid hormones, which subsequently decreased the transcription of the Lhcgr gene (potentially through feedback inhibition) and increased the rate of degradation of Lhcgr mRNA. However, receptor-mediated signaling pathways depend primarily on receptor activation rather than induction of receptor expression, and the results presented herein indicate that LH-or 8-BrcAMP-mediated induction of Cyp1b1 mRNA expression was a result of activation of kinase pathways.
LH is a key regulator of growth and differentiation in the testis and stimulates Leydig cell function and testosterone biosynthesis. LH exerts its regulatory effects by binding to LHCGR and stimulating formation of cAMP. The increase in 94 cAMP formation after LH treatment leads to activation of PRKA, which phosphorylates transcription factors such as steroidogenic factor 1 (SF-1, official symbol NR5A1) and cAMP response element-binding protein (CREB). Phosphorylated transcription factors bind to response elements found in the proximal promoter region of steroidogenic CYP genes, leading to increased mRNA transcription and protein expression [11] [12] [13] . For example, LH regulation of steroidogenic enzymes such as CYP11A1, CYP17A1, and CYP19A1 is mediated through the PRKA pathway via phosphorylation of NR5A1 or CREB in MA-10 and R2C Leydig cells [41, 42] . Binding sites for NR5A1 and CREB have been identified in the far upstream enhancer and proximal promoter regions of the Cyp1b1 gene in adrenal cells [43, 44] .
The hormonal regulation of testicular CYP1B1 most closely resembles that of the steroidogenic CYP enzymes such as CYP11A1, CYP17A1, and CYP19A1, although CYP1B1 does not appear to be involved in steroidogenesis. There is considerable experimental evidence, including studies with mouse and rat Leydig cells, showing that Cyp11a1, Cyp17a1, and Cyp19a1 mRNA expression is increased following treatment with LH or cAMP analogs [45, 46] . In addition, the developmental profile of CYP1B1 is similar to that of CYP17A1 and CYP11A1 in mouse and rat Leydig cells [47] . Cyp1b1, Cyp11a1, and Cyp17a1 genes are expressed in fetal Leydig cells and show a pubertal increase in expression, generally around Gestational Day 20, which precedes the rise in intratesticular testosterone concentration and parallels the increase in Lhcgr mRNA levels [11, 42, 48] . It is curious that Cyp1b1 expression is regulated in parallel with genes known to be required for androgen biosynthesis and Leydig cell function even though CYP1B1 is not known to be involved in androgen synthesis. We postulate that CYP1B1 may be involved in the metabolism of estradiol in this tissue, but we have not yet established a connection between LH-regulated CYP1B1 and estradiol metabolism in Leydig tumor cells. There are several reports that MA-10 and R2C cells express estrogen receptor [49] [50] [51] [52] [53] , and it has been shown that R2C cells can synthesize estrogen upon addition of androstenedione [23, 54] . Thus, it is likely that estrogen is present and functional in Leydig tumor cells. Estradiol has been shown to be capable of inhibiting steroidogenesis in Leydig cells by down-regulating the expression of Cyp11a1 and Cyp17a1 [55] , and it has been hypothesized that the estrogen:androgen balance in vivo is a critical determinant of Leydig cell function [56] . It is therefore tempting to speculate that the metabolism of estrogen by CYP1B1 could be important in maintaining the estrogen:androgen balance in testis and Leydig tumor cells.
In summary, the present study demonstrated that CYP1B1 expression in MA-10 mouse Leydig cells and R2C rat Leydig cells was induced by LH in a concentration-and timedependent manner and was accompanied by increased PRKA activity. Moreover, basal CYP1B1 expression, as well as induction of CYP1B1, was linked to PRKA activity but not to PRKC or PRKG activities. Thus, testicular CYP1B1 expression is regulated by LH through a PRKA-mediated pathway.
